ARGENX SE (ARGX.BR) Stock Fundamental Analysis
Europe - EBR:ARGX - NL0010832176 - Common Stock
796 EUR
+3.6 (+0.45%)
We assign a fundamental rating of 6 out of 10 to ARGX. ARGX was compared to 75 industry peers in the Biotechnology industry. While ARGX has a great health rating, its profitability is only average at the moment. ARGX is growing strongly while it is still valued neutral. This is a good combination! With these ratings, ARGX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year ARGX was profitable.
ARGX had a positive operating cash flow in the past year.
In the past 5 years ARGX reported 4 times negative net income.
ARGX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ARGX has a Return On Assets of 17.84%. This is amongst the best in the industry. ARGX outperforms 90.67% of its industry peers.
With an excellent Return On Equity value of 21.00%, ARGX belongs to the best of the industry, outperforming 88.00% of the companies in the same industry.
ARGX's Return On Invested Capital of 5.71% is amongst the best of the industry. ARGX outperforms 81.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROIC | 5.71% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ARGX has a Profit Margin of 41.97%. This is amongst the best in the industry. ARGX outperforms 93.33% of its industry peers.
Looking at the Operating Margin, with a value of 15.30%, ARGX belongs to the top of the industry, outperforming 82.67% of the companies in the same industry.
ARGX has a better Gross Margin (89.40%) than 82.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ARGX is destroying value.
ARGX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ARGX has been increased compared to 5 years ago.
Compared to 1 year ago, ARGX has a worse debt to assets ratio.
2.2 Solvency
ARGX has an Altman-Z score of 32.85. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 32.85, ARGX belongs to the top of the industry, outperforming 97.33% of the companies in the same industry.
ARGX has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
ARGX has a Debt to FCF ratio of 0.14. This is amongst the best in the industry. ARGX outperforms 96.00% of its industry peers.
ARGX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ARGX's Debt to Equity ratio of 0.01 is amongst the best of the industry. ARGX outperforms 84.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 32.85 |
ROIC/WACC0.76
WACC7.52%
2.3 Liquidity
ARGX has a Current Ratio of 5.60. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
ARGX has a Current ratio of 5.60. This is amongst the best in the industry. ARGX outperforms 81.33% of its industry peers.
ARGX has a Quick Ratio of 5.27. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ARGX (5.27) is better than 82.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1512.50%, which is quite impressive.
The Revenue has grown by 64.65% in the past year. This is a very strong growth!
ARGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 94.61% yearly.
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
Revenue 1Y (TTM)64.65%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%91.37%
3.2 Future
Based on estimates for the next years, ARGX will show a very strong growth in Earnings Per Share. The EPS will grow by 106.11% on average per year.
Based on estimates for the next years, ARGX will show a very strong growth in Revenue. The Revenue will grow by 33.99% on average per year.
EPS Next Y867.29%
EPS Next 2Y297.24%
EPS Next 3Y171.03%
EPS Next 5Y106.11%
Revenue Next Year89.57%
Revenue Next 2Y60.07%
Revenue Next 3Y45.87%
Revenue Next 5Y33.99%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 74.25, the valuation of ARGX can be described as expensive.
Based on the Price/Earnings ratio, ARGX is valued a bit cheaper than 74.67% of the companies in the same industry.
When comparing the Price/Earnings ratio of ARGX to the average of the S&P500 Index (25.56), we can say ARGX is valued expensively.
With a Price/Forward Earnings ratio of 33.80, ARGX can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ARGX indicates a somewhat cheap valuation: ARGX is cheaper than 80.00% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of ARGX to the average of the S&P500 Index (34.62), we can say ARGX is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 74.25 | ||
| Fwd PE | 33.8 |
4.2 Price Multiples
ARGX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ARGX is cheaper than 73.33% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ARGX is valued a bit cheaper than 78.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 184.04 | ||
| EV/EBITDA | 103.99 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 171.03% in the coming years.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y297.24%
EPS Next 3Y171.03%
5. Dividend
5.1 Amount
No dividends for ARGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EBR:ARGX (11/18/2025, 11:19:14 AM)
796
+3.6 (+0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners41.51%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap49.01B
Revenue(TTM)3.60B
Net Income(TTM)1.28B
Analysts84.8
Price Target738.11 (-7.27%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)7.11%
Max EPS beat(2)23.2%
EPS beat(4)3
Avg EPS beat(4)3962.36%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)1996.71%
EPS beat(12)8
Avg EPS beat(12)1343.38%
EPS beat(16)12
Avg EPS beat(16)1012.62%
Revenue beat(2)1
Avg Revenue beat(2)3.68%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.17%
Revenue beat(4)3
Avg Revenue beat(4)5.02%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)6
Avg Revenue beat(8)5.96%
Revenue beat(12)10
Avg Revenue beat(12)14%
Revenue beat(16)13
Avg Revenue beat(16)17.53%
PT rev (1m)0.38%
PT rev (3m)3.9%
EPS NQ rev (1m)-0.95%
EPS NQ rev (3m)5.27%
EPS NY rev (1m)6.84%
EPS NY rev (3m)42.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.89%
Revenue NY rev (1m)2.3%
Revenue NY rev (3m)12.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 74.25 | ||
| Fwd PE | 33.8 | ||
| P/S | 18.62 | ||
| P/FCF | 184.04 | ||
| P/OCF | 140.72 | ||
| P/B | 9.32 | ||
| P/tB | 9.67 | ||
| EV/EBITDA | 103.99 |
EPS(TTM)10.72
EY1.35%
EPS(NY)23.55
Fwd EY2.96%
FCF(TTM)4.33
FCFY0.54%
OCF(TTM)5.66
OCFY0.71%
SpS42.74
BVpS85.4
TBVpS82.33
PEG (NY)0.09
PEG (5Y)N/A
Graham Number143.52
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROCE | 7.61% | ||
| ROIC | 5.71% | ||
| ROICexc | 15.87% | ||
| ROICexgc | 17.62% | ||
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% | ||
| FCFM | 10.12% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.07 | ||
| Cap/Depr | 428.74% | ||
| Cap/Sales | 3.12% | ||
| Interest Coverage | 519.07 | ||
| Cash Conversion | 82.6% | ||
| Profit Quality | 24.11% | ||
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 32.85 |
F-Score5
WACC7.52%
ROIC/WACC0.76
Cap/Depr(3y)176.19%
Cap/Depr(5y)545.91%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
EPS Next Y867.29%
EPS Next 2Y297.24%
EPS Next 3Y171.03%
EPS Next 5Y106.11%
Revenue 1Y (TTM)64.65%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%91.37%
Revenue Next Year89.57%
Revenue Next 2Y60.07%
Revenue Next 3Y45.87%
Revenue Next 5Y33.99%
EBIT growth 1Y207%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1305.72%
EBIT Next 3Y205.97%
EBIT Next 5Y121.7%
FCF growth 1Y140.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y161.79%
OCF growth 3YN/A
OCF growth 5YN/A
ARGENX SE / ARGX.BR FAQ
What is the fundamental rating for ARGX stock?
ChartMill assigns a fundamental rating of 6 / 10 to ARGX.BR.
What is the valuation status of ARGENX SE (ARGX.BR) stock?
ChartMill assigns a valuation rating of 5 / 10 to ARGENX SE (ARGX.BR). This can be considered as Fairly Valued.
Can you provide the profitability details for ARGENX SE?
ARGENX SE (ARGX.BR) has a profitability rating of 5 / 10.
Can you provide the expected EPS growth for ARGX stock?
The Earnings per Share (EPS) of ARGENX SE (ARGX.BR) is expected to grow by 867.29% in the next year.